gvtcx

GB-Liverpool: LW072 Tender for Albendazole and Placebo for a Phase 2 Clinical Trial

Liverpool School of Tropical Medicine Published 11 Nov 2022 Contracts Finder

key details

Value£100,000
Statusactive
Category (CPV) 73100000
RegionNorth West
Deadline6 Dec 2022
Contract start2 Jan 2023
Contract end31 Dec 2024
Procedureopen
SME suitableYes
OCIDocds-b5fd17-c6faa565-4d11-42e6-ad8b-8ec5c23fb329

description

STM, together with colleagues at the Department of Chemistry of the University of Liverpool (UoL), The University Hospital Bonn, the University of Buea in Cameroon and the Japanese pharmaceutical company Eisai, are developing a new drug to target the neglected tropical diseases lymphatic filariasis (LF) and onchocerciasis. These are both debilitating infections that affect more than 150 million people globally. The drug candidate, AWZ1066S is funded to enter a Phase II clinical trial in 2023 and the design of the trial requires the supply of Albendazole and an Albendazole placebo for use in the clinical trial.

Additional information: The contracting authority considers that this contract may be suitable for economic operators that are small or medium enterprises (SMEs). However, any selection of tenderers will be based solely on the criteria set out for the procurement.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
11 Nov 2022 Tender (tender) · b8b65624-6a9a-44e9-b9b0-4c755c37657f-589353

more from Liverpool School of Tropical Medicine

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.